According to CoinMeta, Changchun High-Tech announced that its holding subsidiary, Jinsai Pharmaceutical, has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The registration clinical trial application for the domestic production of its GenSci161 injection has been approved, allowing the conduct of clinical trials for the indication of connective tissue disease-related interstitial lung disease ( CTD-ILD ). GenSci161 injection is a Class 1 therapeutic biological product, and its previous clinical trial applications for endometriosis, moderate to severe hidradenitis suppurativa, and non-infectious uveitis have already been approved.